Repurposing of CAST Systems as Next-Generation Tools for Genome Engineering of Mammalian Cells
INTETOOLS aims to enhance genome engineering by repurposing CRISPR Associated Transposon systems for precise insertion of large DNA cargos in eukaryotic genomes, overcoming current limitations.
Projectdetails
Introduction
Genome editing using RNA-guided CRISPR-Cas nucleases (Clustered Regularly Interspaced Short Palindromic Repeats that associate with CRISPR associated proteins) has radically altered life sciences, enabling genome manipulation in living organisms. However, their use is limited by dependence on DNA Damage Response (DDR), which restricts genome editing to dividing cells.
Limitations of Current Technologies
Further, these nucleases cannot handle DNA cargos large enough to harbor regulatory DNA circuitry, thus precluding genome engineering. In INTETOOLS, I will overcome these limitations by dissecting and repurposing CRISPR Associated Transposon (CAST) systems into genome engineering tools.
Overview of CAST Systems
CASTs are naturally occurring prokaryotic protein–RNA machineries consisting of an inactive CRISPR effector complex, which associate with Tn7 family transposons to insert large DNA cargos. Knowledge of their molecular mechanisms is scarce, which prevents their practical application in genome engineering.
Objectives of the Project
Objective 1
In Objective 1, I will investigate the architecture of different CASTs to obtain fundamental knowledge of their RNA-guided integration.
Objective 2
I will then use this knowledge in Objective 2 to dissect their mechanism underpinnings whereby CRISPR-Cas complexes associate with transposition complexes to insert with nucleotide accuracy DNA cargos.
Objective 3
This will inform Objective 3, where I will design new CAST tools that will allow RNA-guided transposition in eukaryotic genomes. These revamped CASTs will be capable of inserting large DNAs with high precision, harboring regulatory regions into eukaryotic genomes, enabling genome engineering in eukaryotes.
Experimental Validation
I will test the redesigned CASTs in mammalian cell lines and at the organismal level by rescuing the eyeless mutant phenotype in Drosophila melanogaster.
Impact of INTETOOLS
INTETOOLS will catalyze a conceptual leap propelling the field into a new era of genome engineering, with major biomedical and biotechnological applications, especially in synthetic biology.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.475.491 |
Totale projectbegroting | € 2.475.491 |
Tijdlijn
Startdatum | 1-11-2023 |
Einddatum | 31-10-2028 |
Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- KOBENHAVNS UNIVERSITETpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Molecular mechanisms, functions and applications of RNA-guided DNA transposonsThis project aims to enhance understanding of RNA-guided DNA transposons to develop advanced genome editing tools for biotechnology and precision medicine. | ERC Starting... | € 1.499.403 | 2024 | Details |
Profile nucleases and Repurpose Off-Targets to Expand Gene EditingThe PROTÉGÉ project aims to enhance gene editing safety and diversity by profiling programmable nucleases and exploring off-target effects for improved precision in genetic therapies. | ERC Starting... | € 1.141.779 | 2023 | Details |
Harnessing a novel CRISPR nuclease for programmable counterselection in human cellsThis project aims to enhance CRISPR genome editing efficiency by developing a programmable counter-selection mechanism to eliminate unedited cells, thereby reducing screening burdens in various applications. | ERC Proof of... | € 150.000 | 2024 | Details |
Transcriptional Engineering of Hematopoietic Stem Cells using CRISPRThis project aims to enhance hematopoietic stem cell therapies by using repurposed CRISPR/Cas systems for precise transcriptional manipulation of key genetic pathways. | ERC Starting... | € 1.499.923 | 2022 | Details |
RNA-based gene writing in human cellsSCRIBE aims to develop innovative RNA-based gene writing strategies using CRISPR and retrotransposons to enhance gene transfer efficacy and safety for research and therapeutic applications. | ERC Consolid... | € 1.999.465 | 2024 | Details |
Molecular mechanisms, functions and applications of RNA-guided DNA transposons
This project aims to enhance understanding of RNA-guided DNA transposons to develop advanced genome editing tools for biotechnology and precision medicine.
Profile nucleases and Repurpose Off-Targets to Expand Gene Editing
The PROTÉGÉ project aims to enhance gene editing safety and diversity by profiling programmable nucleases and exploring off-target effects for improved precision in genetic therapies.
Harnessing a novel CRISPR nuclease for programmable counterselection in human cells
This project aims to enhance CRISPR genome editing efficiency by developing a programmable counter-selection mechanism to eliminate unedited cells, thereby reducing screening burdens in various applications.
Transcriptional Engineering of Hematopoietic Stem Cells using CRISPR
This project aims to enhance hematopoietic stem cell therapies by using repurposed CRISPR/Cas systems for precise transcriptional manipulation of key genetic pathways.
RNA-based gene writing in human cells
SCRIBE aims to develop innovative RNA-based gene writing strategies using CRISPR and retrotransposons to enhance gene transfer efficacy and safety for research and therapeutic applications.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
New Prime Editing and non-viral delivery strategies for Gene TherapyThis project aims to develop non-viral delivery systems and novel prime editors to enhance gene editing efficiency and safety for treating Sickle Cell Disease and other genetic disorders. | EIC Pathfinder | € 4.406.097 | 2022 | Details |
Next generation gene writing platform to cure genetic and oncological diseasesIntegra Therapeutics' FiCAT platform enhances gene therapy by enabling precise and safe insertion of large DNA sequences, aiming to cure genetic and cancer-related diseases. | EIC Accelerator | € 2.496.375 | 2024 | Details |
A revolutionary cell programming platform based on the targeted nano-delivery of a transposon gene editing systemThe NANO-ENGINE project aims to develop an affordable, scalable, and safe DNA-based in vivo cell programming technology using Targeted Nanoparticles to enhance accessibility of cell therapies for various diseases. | EIC Pathfinder | € 2.988.377 | 2023 | Details |
FluEdit: Microfluidics Gen-editing platform voor bloedcellenNTrans Technologies ontwikkelt het Flu-Edit platform om efficiënt en veilig gen-editing therapieën voor bloedziekten te realiseren met behulp van microfluidics en iTOP technologie. | Mkb-innovati... | € 20.000 | 2023 | Details |
New Prime Editing and non-viral delivery strategies for Gene Therapy
This project aims to develop non-viral delivery systems and novel prime editors to enhance gene editing efficiency and safety for treating Sickle Cell Disease and other genetic disorders.
Next generation gene writing platform to cure genetic and oncological diseases
Integra Therapeutics' FiCAT platform enhances gene therapy by enabling precise and safe insertion of large DNA sequences, aiming to cure genetic and cancer-related diseases.
A revolutionary cell programming platform based on the targeted nano-delivery of a transposon gene editing system
The NANO-ENGINE project aims to develop an affordable, scalable, and safe DNA-based in vivo cell programming technology using Targeted Nanoparticles to enhance accessibility of cell therapies for various diseases.
FluEdit: Microfluidics Gen-editing platform voor bloedcellen
NTrans Technologies ontwikkelt het Flu-Edit platform om efficiënt en veilig gen-editing therapieën voor bloedziekten te realiseren met behulp van microfluidics en iTOP technologie.